LabCorp

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

Founded in 2013, Olaris is dedicated to transforming disease diagnosis and treatment. Utilizing its CEREBRO platform, which integrates metabolomics and machine learning, the company discovers and develops precision diagnostics under its myOLARIS™ brand.

BioReference Health - Laboratory Testing Businesses focused on oncology and oncology-related clinical testing services.

Percipio Health is a healthcare technology company that leverages artificial intelligence to enhance patient care. It provides a platform that integrates advanced computer vision software to monitor and assess patient health status. This technology enables clinicians and caregivers to maintain a comprehensive view of a patient's well-being and accurately identify medications. By offering AI-driven insights, Percipio Health empowers healthcare providers to make informed decisions, ultimately improving the quality of care delivered to patients.

Teal Health specializes in developing at-home cervical cancer screening devices, aiming to enhance convenience, privacy, and accessibility for women. Their FDA-approved platform includes a sampling device, virtual consultations with licensed providers, secure laboratory testing, an online results portal, and coordination of follow-up care.

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

Praia Health is an innovative digital health company that focuses on enhancing the delivery of personalized health solutions for hospitals and their patients. The company's platform is designed to facilitate the digital transformation of health systems by streamlining and customizing health journeys. It connects patients with appropriate services, products, and resources, thereby creating comprehensive patient profiles that extend beyond traditional clinical records. This approach enables hospitals to sustain stronger relationships with their patients and provide more specialized care throughout their health experiences.

GLX Analytix combines proprietary blood biomarkers with AI to pioneer personalized medicine. Its platform enables earlier diagnosis and optimized treatment plans for various diseases such as neurodegeneration, autoimmunity, cardiovascular disorders, and neuropsychiatric conditions.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

NOWDiagnostics develops and manufactures rapid diagnostic tests that use a single drop of blood, providing results within minutes. Its ADEXUSDx product line offers tests for common conditions like pregnancy, heart attack, and toxicology, empowering patients and caregivers with immediate healthcare insights.

Acclinate is a high-growth company that focuses on enhancing diversity and representation in genomic research and clinical trials through its digital health platform. By leveraging machine learning and predictive analytics, Acclinate automates the processes of identifying, educating, engaging, and retaining diverse participants for genomic studies. This approach not only empowers communities to take proactive steps towards better health but also helps biopharmaceutical research organizations reduce the overall costs associated with drug development. Through sustained engagement and AI-driven insights, Acclinate aims to transform the landscape of clinical research and improve health outcomes for underrepresented populations.

Founded in 2017, Phenomix Sciences is a biotechnology company specializing in metabolomics and genomics. It develops precision medicine tools for chronic disease management, focusing on obesity. The company's AI-driven platform offers a novel blood test to classify patients' unique pathophysiological phenotypes, enabling personalized treatment with improved efficacy and fewer side effects.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Prolocor is a biotechnology company based in Philadelphia, PA. Founded in 2020, it specializes in developing diagnostic tests for cardiovascular diseases. The company aims to provide more precise methods and tools for assessing and managing risk in cardiovascular disease.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

HealthEC develops comprehensive technology solutions for exchanging healthcare information and managing population health globally. Its Population Health Management platform integrates critical components into a single platform, serving hospitals, providers, ACOs, health plans, and employers.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Baystate Health is an integrated healthcare system serving nearly one million people in western Massachusetts.

Evvy is a company focused on women's health, specializing in at-home vaginal microbiome tests aimed at closing the gender health gap. By utilizing metagenomic sequencing, Evvy's tests analyze individual symptoms and assess risks related to significant health issues. The company provides personalized reports that empower women with insights into their bodies, facilitating a better understanding of their health and promoting overall well-being.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that integrate devices, software, and services to support patients in monitoring their health and managing diseases. By bridging the gap between diagnosis and treatment, Vital Bio aims to empower patients and healthcare providers alike, promoting proactive care and reducing disparities in health outcomes. The company's innovative approach seeks to enhance the overall healthcare experience, ensuring that individuals have greater control over their health management.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Mercy BioAnalytics is a biotechnology company dedicated to improving and saving lives through early cancer detection. Founded in 2018, it has developed a proprietary platform that uses extracellular vesicles (EVs) in blood to detect stage I cancer.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

Clinical Outreach Laboratory Services provides all medical and clinical trials.

Prolocor is a biotechnology company based in Philadelphia, PA. Founded in 2020, it specializes in developing diagnostic tests for cardiovascular diseases. The company aims to provide more precise methods and tools for assessing and managing risk in cardiovascular disease.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Circuit Clinical is an integrated research organization that has emerged from the experience of a physician engaged in clinical research within a private practice. Established in 2015, the company aims to enhance the way clinical research is conducted by emphasizing physician and participant engagement. Circuit Clinical leverages a network of over 1 million patients, utilizing direct HIPAA/FDA-compliant Electronic Medical Record reviews to identify motivated participants. The organization provides research services that facilitate access to clinical research, guiding both experienced and novice community physicians and their patients through each step of the clinical research process. Through its technology products and focus on participant and physician experience, Circuit Clinical seeks to improve research site quality and patient safety, creating a more efficient pathway for clinical research.

Getlabs is a digital health platform that facilitates at-home diagnostics. It enables healthcare organizations to send mobile phlebotomists to patients' homes nationwide for lab draws, vital checks, and advanced diagnostics, improving patient adherence and care gap closure.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

PetDx is a San Diego-based molecular diagnostics company that specializes in the early detection of cancer in pets through innovative liquid biopsy technology. The company's main product, OncoK9, is a first-in-class multi-cancer early detection test that allows veterinarians to identify cancer in dogs using a simple blood draw. By utilizing advanced genomic analysis, including next-generation sequencing and proprietary bioinformatics algorithms, PetDx empowers veterinarians to enhance the care they provide to canine patients. The company's focus on non-invasive testing and customized assays positions it at the forefront of veterinary oncology, aiming to revolutionize how cancer is detected, characterized, and managed in pets.

Toxikon Corp., founded in 1977 by Dr. Laxman Desai, is a preclinical contract research organization based in Bedford, Massachusetts. Initially established as Cambridge Diagnostics, the company has a long history of advancing innovations in the pharmaceutical, biotechnology, and medical device industries. Toxikon offers a comprehensive range of in vivo, in vitro, and analytical testing services that facilitate the progression of therapies from initial concept through research, development, trials, and commercialization. Over the years, Toxikon has expanded its capabilities significantly, including the acquisition of the former American Biogenics facility and the addition of a neighboring laboratory space, which enhances its capacity for bioanalytical support and large animal models. With over three decades of experience, Toxikon is dedicated to helping clients navigate the complexities of regulatory approval processes, ensuring that products reach the market efficiently and effectively.

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Ovia Health is a digital healthcare company that provides a comprehensive maternity and family benefits solution, enhancing support for women and families during their parenthood journey. Originally known as Ovuline, the company offers a suite of mobile applications, including Ovia Fertility and Ovia Pregnancy, which deliver personalized information and resources related to fertility, pregnancy, and parenting. By empowering women with customized health insights, Ovia Health enables them to take control of their reproductive health and navigate the complexities of starting a family with confidence. The company's focus on integrating healthcare into everyday life positions it as a valuable resource for families seeking to improve their well-being throughout the parenting experience.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

Biospectal is a remote patient monitoring and biosensing software company that has developed the OptiBP smartphone app, which allows users to measure and monitor blood pressure with medical-grade accuracy using their smartphones. The app utilizes the phone's built-in camera to optically measure blood flow from the user's fingertip, providing results in approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal's proprietary algorithms interpret the captured data to deliver accurate blood pressure readings. The OptiBP app is currently available in public beta for Android users in several countries, including the United States, United Kingdom, France, Germany, Spain, and Switzerland. This innovative approach enables users to perform blood pressure measurements anytime and anywhere without the need for additional devices or accessories.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms

TrakCel provides a cloud‑based platform that integrates and manages the entire supply chain for autologous and allogeneic cell and gene therapies. The system tracks program data, documents processes, and prepares regulatory audit materials, helping developers avoid the delays and costs of paper‑based workflows. It serves medical centers, logistics providers, manufacturers, and trial sponsors, and is used by both commercial and academic organizations to advance human health. Founded in 2012, the company is headquartered in Cardiff, United Kingdom.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Circuit Clinical is an integrated research organization that has emerged from the experience of a physician engaged in clinical research within a private practice. Established in 2015, the company aims to enhance the way clinical research is conducted by emphasizing physician and participant engagement. Circuit Clinical leverages a network of over 1 million patients, utilizing direct HIPAA/FDA-compliant Electronic Medical Record reviews to identify motivated participants. The organization provides research services that facilitate access to clinical research, guiding both experienced and novice community physicians and their patients through each step of the clinical research process. Through its technology products and focus on participant and physician experience, Circuit Clinical seeks to improve research site quality and patient safety, creating a more efficient pathway for clinical research.

Dorsata, Inc. is a healthcare technology company that specializes in providing an online platform for the development, sharing, and application of clinical care pathways. Founded in 2011 and headquartered in Arlington, Virginia, Dorsata's platform enhances collaboration among healthcare providers by enabling them to create and utilize defined workflows for efficient decision-making, documentation, and order entry. By leveraging clinician-developed care pathways, the company aims to improve healthcare quality and reduce costs. Additionally, Dorsata has developed a prenatal record platform that allows providers to manage electronic health records effectively, offering a user-friendly experience and a rules engine that helps create tailored care plans for patients throughout their pregnancy.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

Weavr Health develops blood collection devices that enable patients to collect clinical-grade blood samples without a phlebotomist, including at-home collection. The devices perform essential sample processing steps without trained professionals or specialized laboratory equipment, allowing diagnostic tests to be conducted at the point of care and expanding access to care.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, that specializes in developing medical products and research tools focused on male fertility management. Founded in 2012, the company manufactures innovative devices such as the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a tool for remote blood sampling that facilitates comprehensive diagnostic testing. Additionally, Sandstone offers the Trak fertility system, which includes an engine, a disposable test plate, a sample collection cup, and a dropper, enabling men to monitor their sperm quality and take proactive steps toward improving their fertility. The accompanying Trak mobile application allows users to track their fertility data over time, identify potential fertility issues, and enhance their chances of conception. Sandstone Diagnostics aims to empower couples to manage their reproductive health in the comfort and privacy of their homes.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

The Recovery Platform is a medical enterprise dedicated to enhancing medication-assisted treatment (MAT) for substance use disorders. It provides a specialized platform that supports both physicians and patients in adhering to treatment protocols. The platform offers a comprehensive suite of tools designed to monitor patient compliance, track progress, and facilitate telehealth communication, as well as manage scheduling. By streamlining these processes, the Recovery Platform aids physicians in guiding their patients through the transition from opioid dependence to recovery, ensuring that compliance requirements are effectively managed while promoting best practices in treatment.

Chiltern International Limited is a prominent contract research organization that specializes in clinical development and scientific services for the pharmaceutical and biotechnology sectors. The company offers a comprehensive range of services, including early and late-phase clinical development, biostatistics, and medical and regulatory affairs. Chiltern serves various specialty areas within the biopharmaceutical and medical device industries, utilizing diverse engagement models to meet the specific needs of its clients. In addition to its clinical services, Chiltern also provides resourcing solutions to support the operational requirements of its partners. Through its expertise and collaborative technologies, the company plays a crucial role in advancing clinical research and development.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

Sera Prognostics, Inc. is a biotechnology company that develops diagnostic tests to predict a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy complications. Using proteomics and bioinformatics, it discovers and commercializes blood-based biomarker tests and predictive analytics to guide early, personalized interventions and reduce healthcare costs associated with pregnancy complications. Founded in 2008 and based in Salt Lake City, Utah, Sera aims to improve maternal and neonatal outcomes by providing physicians with actionable risk information during pregnancy.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. Founded in 1975, the company specializes in providing a range of diagnostic services to healthcare providers and their patients across the United States. Its offerings include cytology and pathology services, as well as ancillary testing such as the Digene Hybrid Capture 2 for human papillomavirus (HPV), testing for gonorrhea and chlamydia, and immunohistochemistry. ClearPath also conducts frozen section analysis and provides in situ hybridization services to detect HPV and assess Her-2/neu gene amplification in breast cancer. Additionally, the company offers triple testing to identify vaginitis pathogens and Vysis UroVysion testing for the non-invasive evaluation of bladder cancer. Through its comprehensive diagnostic capabilities, ClearPath Diagnostics plays a vital role in enhancing patient care and treatment outcomes.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Calif.-based laboratory firm

Safe Food International (SFI) is an organization headquartered in Washington, D.C., dedicated to enhancing global food safety. It collaborates with consumer organizations worldwide to address critical food safety issues. SFI's initiatives focus on ensuring that national food safety programs are effective in tackling common challenges, such as the approval of food products before consumption or export, and in preventing intentional contamination of food supplies. Through awareness programs, SFI aims to promote safer food practices and advocate for stronger food safety standards across different regions.

Ativa Medical Corporation is a medical device manufacturing company based in Saint Paul, Minnesota, founded in 2008. The company specializes in developing and commercializing point of care testing medical diagnostics products aimed at decentralized healthcare settings. Ativa Medical focuses on providing rapid diagnostic test results for critical hematology and clinical chemistry tests, utilizing advanced microfluidics technology. Its product offerings include analyzers and disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. These products cater to various healthcare environments, including hospital departments, physician's offices, and remote healthcare clinics, enhancing the speed and accessibility of medical diagnostics.

Bode Technology Group, Inc. specializes in human DNA analysis and innovative collection products primarily for law enforcement and identification markets. The company offers a comprehensive range of services, including high-throughput DNA testing, casework analysis, missing person identification, and databanking of convicted offenders and arrestees. Bode's patented DNA collection systems are utilized globally for gathering DNA from various sources, including crime scenes and familial relationships for genealogy purposes. Their teams of analysts and researchers continuously explore advanced methodologies and technologies to enhance the analysis of challenging samples, such as bones and aged tissue. Additionally, Bode provides customized consulting, training, and validation services, reinforcing its commitment to supporting law enforcement agencies and state governments in their forensic endeavors.

Vivify Health Inc. is a digital health company based in Plano, Texas, founded in 2009. It operates a cloud-based, device-agnostic platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This innovative platform aims to reduce hospital readmissions and overall healthcare costs by enabling automatic remote biometric data collection and delivering tailored care plans. Vivify Health also offers a range of personal health devices, including tablets, weight scales, and pulse oximeters, to enhance patient engagement and support virtual interactions between patients and healthcare professionals. The company is a subsidiary of Optum, Inc. and has established a strategic alliance with AT&T to further its mission of improving population health and patient satisfaction.

Covance Inc. is a leading provider of contract research services focused on the pharmaceutical, biotechnology, and medical device industries. Established in 1987 and headquartered in Princeton, New Jersey, the company offers a comprehensive suite of early- and late-stage development services, including preclinical and clinical pharmacology, biomarker services, and full management of Phase II and III clinical studies. Additionally, Covance provides laboratory testing services to the chemical, agrochemical, and food industries, positioning itself as a market leader in toxicology, central laboratory services, and clinical trial management. The company is known for its extensive experience and specialized expertise, having contributed to the development of the top 50 prescription drugs available today. As part of Laboratory Corporation of America Holdings, Covance is dedicated to advancing healthcare by helping clients reduce the time and costs associated with drug development through high-quality nonclinical, clinical, and commercialization services.

LipoScience is a Raleigh, North Carolina-based company specializing in personalized diagnostics through the use of nuclear magnetic resonance (NMR) technology. The company has developed the NMR LipoProfile test, its flagship diagnostic tool, which quantitatively measures low density lipoprotein particles (LDL-P) in blood samples. This test provides physicians and patients with critical information to tailor heart disease risk management effectively. Since its inception, LipoScience has seen significant adoption, with over 8 million NMR LipoProfile tests ordered to date.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

Stateless Networks Inc. specializes in providing performance infrastructure and networking solutions tailored for enterprises, service providers, and the federal government. Founded in 2012 and headquartered in San Francisco, the company develops innovative software such as the Stateless AutoWare SDN Fabric Manager, which enhances network management through server-class monitoring capabilities. This technology accelerates deployments, improves system resilience, automates administrative tasks, and facilitates rapid recovery after equipment failures. By leveraging a combination of deep network understanding and advanced distributed systems, Stateless Networks aims to transform network operations for software-centric environments. The company collaborates with leading network and infrastructure vendors to deliver solutions that optimize performance and visibility in enterprise data centers.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Medtox Scientific operates a SAMHSA-certified drug testing laboratory, a CAP and CLIA-certified clinical laboratory, and an FDA-registered diagnostic division. The company provides comprehensive laboratory and diagnostic testing services, including medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. Medtox Scientific is committed to delivering excellent customer service, ensuring efficient and effective operation of clients' testing programs. The company serves a diverse range of clients, including physician offices, corporations, clinics, health organizations, and government agencies, with a focus on building strong relationships and being responsive to client needs.

Clearstone Central Laboratories is the largest and most experienced private company.

Orchid Cellmark Ltd. provides genotyping and DNA testing services for forensic, human identity testing, and agricultural applications.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. is a provider of consultative laboratory testing solutions that specializes in anatomic and molecular pathology services. The company offers a range of testing options including diagnostic cytopathology, histopathology, and immunohistochemistry, along with a selection of antibodies for biomarker analysis. DCL Medical Laboratories also caters to clinical trials clients and provides reference testing services for hospitals and other laboratories, with a particular emphasis on women's health. Its testing portfolio includes ThinPrep Pap test processing and screening, HPV molecular testing, chlamydia and gonorrhea testing, and cystic fibrosis carrier screening for pre-conceptual and prenatal assessments. Serving the medical industry across the United States, DCL Medical Laboratories is dedicated to delivering high-quality diagnostic services tailored to meet the needs of its clients.

Monogram Biosciences is a leading developer of innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company specializes in molecular diagnostics and offers products such as Trofile, an assay that determines the tropism of a patient's HIV, facilitating personalized treatment options. Additionally, Monogram provides VeraTag technology, which enhances the development of targeted therapeutics. The company's solutions cater to healthcare providers and pharmaceutical companies, contributing to advancements in precision medicine and improving patient outcomes.

Tandem Labs is a bioanalytical contract research organization based in Salt Lake City, Utah, founded in 1995. It specializes in providing comprehensive support to pharmaceutical, biopharmaceutical, and biotechnology companies throughout their clinical and preclinical drug development programs. Tandem Labs offers a wide range of services, including mass spectrometry and immunochemistry, to facilitate bioanalytical studies. Its capabilities encompass GLP bioanalytical services such as method development and validation, clinical and preclinical sample analysis, and pharmacokinetic analysis. Additionally, the organization provides rapid turnaround non-GLP discovery services and specialized immunoanalytical testing. In 2008, Tandem Labs was acquired by LabCorp, further enhancing its position in the industry.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Litholink Corp is a clinical laboratory based in Chicago, Illinois, specializing in kidney disease management. The company offers 24-hour urine testing services aimed at kidney stone prevention, providing accurate test results and personalized treatment recommendations for patients. Litholink's national infrastructure supports seamless integration of its services, ensuring high levels of customer support and convenience for clients managing their laboratory needs.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and exceptional customer service. The company offers a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to laboratory testing for physician specialists, Esoterix provides clinical trial services and various support services, including information technology, managed care, and billing. Its commitment to innovation is evident in the development of new products designed to meet the evolving needs of the healthcare sector.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Systems delivers pathology testing services that combine academic expertise with personalized local care, covering dermatopathology, gastrointestinal pathology, and uropathology.

Dynacare is a clinical laboratory offering services in the U.S. and Canada, operating central labs, rapid response labs, and patient service centers to provide clinical testing for healthcare providers.

Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity.

ViroMed Laboratories is an FDA-registered laboratory specializing in infectious disease testing. As part of LabCorp's Specialty Testing Group, the company offers a range of laboratory testing services tailored to support clients involved in human cells, tissues, and cellular and tissue-based products (HCT/Ps). Its services include testing for reproductive donors, tissue and eye banks, bone marrow and stem cells, cord blood, and blood. ViroMed Laboratories serves various sectors, including biotechnology, pharmaceuticals, medical devices, and integrated healthcare, ensuring comprehensive support for its diverse clientele.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.